Do analysts prefer ACB or TLPH?

Talphera has a consensus target price of $3.00, indicating a potential upside of 191.26%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ACB or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -33.57% 0.10% 0.07% Talphera N/A -92.98% -53.22%

Which has better earnings & valuation, MDWD or TLPH?

Talphera has lower revenue, but higher earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 11.51 -$23.88M -$2.26 N/A Talphera $30K 1,781.90 -$14.29M -$0.31 N/A

Is MDWD or TLPH more profitable?

Talphera has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -180.30% -67.22% -31.87% Talphera N/A -92.98% -53.22%

Which has stronger valuation & earnings, TLPH or EQ?

Talphera has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 1,781.90 -$14.29M -$0.31 N/A Equillium $41.10M 4.65 -$22.40M -$0.32 N/A

Is TLPH or EQ more profitable?

Equillium's return on equity of -61.43% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% Equillium N/A -61.43% -53.72%

Which has stronger earnings & valuation, TLPH or DERM?

Journey Medical has higher revenue and earnings than Talphera. Journey Medical is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 1,781.90 -$14.29M -$0.31 N/A Journey Medical $64.68M 2.82 -$11.43M -$0.37 N/A

Talphera (TLPH) Competitors

$1.03 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.01 (-0.49%)

As of 08:05 AM Eastern

Compare

TLPH vs. TNXP, ACB, MDWD, EQ, and DERM

Should you buy Talphera stock or one of its competitors? MarketBeat compares Talphera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talphera include Tonix Pharmaceuticals (TNXP), Aurora Cannabis (ACB), MediWound (MDWD), Equillium (EQ), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Talphera compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 1 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Tonix Pharmaceuticals' score of 1.62 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Very Positive
Talphera	Very Positive

Talphera has lower revenue, but higher earnings than Tonix Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	16.07	-$124.02M	-$14.36	N/A
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A

Tonix Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 81.54%. Talphera has a consensus price target of $3.00, indicating a potential upside of 191.26%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Talphera	N/A	-92.98%	-53.22%

Tonix Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Talphera has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

Talphera beats Tonix Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Talphera compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Aurora Cannabis had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Aurora Cannabis' score of 1.06 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Positive
Talphera	Very Positive

Talphera has a consensus target price of $3.00, indicating a potential upside of 191.26%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has lower revenue, but higher earnings than Aurora Cannabis. Talphera is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$320.59M	0.54	-$88.13M	-$1.56	N/A
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A

Aurora Cannabis has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Talphera has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
Talphera	N/A	-92.98%	-53.22%

Summary

Talphera beats Aurora Cannabis on 10 of the 16 factors compared between the two stocks.

How does Talphera compare to MediWound?

MediWound (NASDAQ:MDWD) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, MediWound and MediWound both had 1 articles in the media. Talphera's average media sentiment score of 1.89 beat MediWound's score of 1.87 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
MediWound	Very Positive
Talphera	Very Positive

MediWound has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Talphera has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Talphera	N/A	-92.98%	-53.22%

Talphera has lower revenue, but higher earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	11.51	-$23.88M	-$2.26	N/A
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A

46.8% of MediWound shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MediWound presently has a consensus target price of $34.00, suggesting a potential upside of 123.83%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 191.26%. Given Talphera's higher probable upside, analysts plainly believe Talphera is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Talphera beats MediWound on 8 of the 13 factors compared between the two stocks.

How does Talphera compare to Equillium?

Talphera (NASDAQ:TLPH) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Equillium's return on equity of -61.43% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Equillium	N/A	-61.43%	-53.72%

Talphera has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Equillium had 2 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Equillium and 1 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Equillium's score of 0.51 indicating that Talphera is being referred to more favorably in the media.

Company	Overall Sentiment
Talphera	Very Positive
Equillium	Positive

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 191.26%. Equillium has a consensus target price of $7.57, suggesting a potential upside of 150.63%. Given Talphera's higher possible upside, equities research analysts clearly believe Talphera is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Talphera has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A
Equillium	$41.10M	4.65	-$22.40M	-$0.32	N/A

37.7% of Talphera shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Talphera and Equillium tied by winning 8 of the 16 factors compared between the two stocks.

How does Talphera compare to Journey Medical?

Talphera (NASDAQ:TLPH) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 191.26%. Journey Medical has a consensus price target of $13.00, suggesting a potential upside of 96.37%. Given Talphera's higher probable upside, equities research analysts clearly believe Talphera is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Journey Medical	-14.82%	-35.57%	-10.88%

Talphera has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

In the previous week, Journey Medical had 2 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Talphera. Talphera's average media sentiment score of 1.89 beat Journey Medical's score of 0.84 indicating that Talphera is being referred to more favorably in the media.

Company	Overall Sentiment
Talphera	Very Positive
Journey Medical	Positive

37.7% of Talphera shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Journey Medical has higher revenue and earnings than Talphera. Journey Medical is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,781.90	-$14.29M	-$0.31	N/A
Journey Medical	$64.68M	2.82	-$11.43M	-$0.37	N/A

Summary

Talphera and Journey Medical tied by winning 7 of the 14 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLPH vs. The Competition

Export

Metric	Talphera	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.46M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.88%	2.67%	6.11%
P/E Ratio	-3.32	19.54	25.88	24.17
Price / Sales	1,781.90	323.79	548.17	99.03
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	2.78	4.21	10.82	6.38
Net Income	-$14.29M	$64.45M	$3.58B	$337.00M
7 Day Performance	4.87%	1.32%	1.92%	-0.23%
1 Month Performance	26.23%	-1.07%	-0.24%	-1.40%
1 Year Performance	120.09%	29.70%	34.40%	27.76%

Talphera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLPH Talphera	3.4066 of 5 stars	$1.03 flat	$3.00 +191.3%	+120.1%	$53.46M	$30K	N/A	19
TNXP Tonix Pharmaceuticals	4.3275 of 5 stars	$11.63 +1.0%	$22.00 +89.2%	-62.1%	$183.64M	$13.11M	N/A	50	Positive News Gap Down
ACB Aurora Cannabis	0.9288 of 5 stars	$3.00 +1.7%	N/A	-31.8%	$180.97M	$247.82M	N/A	1,130
MDWD MediWound	3.5728 of 5 stars	$13.87 -0.6%	$34.00 +145.1%	-21.1%	$179.29M	$16.96M	N/A	80	Gap Up
EQ Equillium	3.2702 of 5 stars	$2.75 -1.8%	$7.57 +175.3%	+874.5%	$177.03M	$41.10M	N/A	40	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLPH) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Talphera (TLPH) Competitors

TLPH vs. TNXP, ACB, MDWD, EQ, and DERM

How does Talphera compare to Tonix Pharmaceuticals?

Summary

How does Talphera compare to Aurora Cannabis?

Summary

How does Talphera compare to MediWound?

Summary

How does Talphera compare to Equillium?

Summary

How does Talphera compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Talphera (TLPH) Competitors

TLPH vs. TNXP, ACB, MDWD, EQ, and DERM

How does Talphera compare to Tonix Pharmaceuticals?

Do insiders and institutionals have more ownership in TNXP or TLPH?

Does the media refer more to TNXP or TLPH?

Which has preferable earnings and valuation, TNXP or TLPH?

Do analysts prefer TNXP or TLPH?

Is TNXP or TLPH more profitable?

Which has more risk and volatility, TNXP or TLPH?

Summary

How does Talphera compare to Aurora Cannabis?

Do insiders & institutionals believe in ACB or TLPH?

Does the media favor ACB or TLPH?

Do analysts prefer ACB or TLPH?

Which has higher earnings and valuation, ACB or TLPH?

Which has more risk & volatility, ACB or TLPH?

Is ACB or TLPH more profitable?

Summary

How does Talphera compare to MediWound?

Does the media refer more to MDWD or TLPH?

Which has more risk & volatility, MDWD or TLPH?

Is MDWD or TLPH more profitable?

Which has better earnings & valuation, MDWD or TLPH?

Do insiders and institutionals hold more shares of MDWD or TLPH?

Do analysts recommend MDWD or TLPH?

Summary

How does Talphera compare to Equillium?

Is TLPH or EQ more profitable?

Which has more risk & volatility, TLPH or EQ?

Does the media prefer TLPH or EQ?

Do analysts rate TLPH or EQ?

Which has stronger valuation & earnings, TLPH or EQ?

Do institutionals and insiders believe in TLPH or EQ?

Summary

How does Talphera compare to Journey Medical?

Do analysts recommend TLPH or DERM?

Is TLPH or DERM more profitable?

Which has more risk & volatility, TLPH or DERM?

Does the media refer more to TLPH or DERM?

Do institutionals & insiders hold more shares of TLPH or DERM?

Which has stronger earnings & valuation, TLPH or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools